36 completed. 36 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 36 | Completed 36 |
| Phase 2 | 1 | Completed 1 |
Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess Pegvisomant - Pituitary Disease | Phase 3 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 12 | 2019-10-21 | 2025-11-06 |
| A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly CAM2029 (octreotide subcutaneous depot) - Acromegaly | Phase 3 | Completed | Camurus AB | 135 | 2019-10-10 | 2025-12-22 |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly CAM2029 (octreotide subcutaneous depot), Matching placebo - Acromegaly | Phase 3 | Completed | Camurus AB | 72 | 2019-08-19 | 2026-08-20 |
| Open-label Treatment in Cushing's Syndrome Levoketoconazole - Cushing Syndrome, Cushing Disease | Phase 3 | Completed | Cortendo AB | 51 | 2019-01-07 | 2025-06-19 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Relacorilant, Placebo - Cushing Syndrome | Phase 3 | Completed | Corcept Therapeutics | 152 | 2018-11-15 | 2025-07-16 |
| Strict IGF-1 Control in Acromegaly Pegvisomant - Acromegaly | Phase 3 | Completed | Unity Health Toronto | 10 | 2017-07-27 | 2021-11-22 |
| Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease osilodrostat, osilodrostat Placebo - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 73 | 2016-10-03 | 2021-11-01 |
| Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly Octreotide capsules - Acromegaly | Phase 3 | Completed | Chiasma, Inc. | 146 | 2016-02-01 | 2022-04-22 |
| Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Pasireotide LAR - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 123 | 2015-03-31 | 2019-12-10 |
| Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Lanreotide Autogel®, Lanreotide Acetate - Acromegaly | Phase 3 | Completed | Ipsen | 128 | 2014-10-01 | 2019-01-29 |
| Treatment for Endogenous Cushing's Syndrome Levoketoconazole - Endogenous Cushing's Syndrome | Phase 3 | Completed | Cortendo AB | 94 | 2014-08-01 | 2021-04-19 |
| Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Octreotide capsules - Acromegaly | Phase 3 | Completed | Chiasma, Inc. | 155 | 2012-03-01 | 2017-08-17 |
| Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 150 | 2011-11-04 | 2018-05-22 |
| An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Pasireotide sub-cutaneous - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 104 | 2011-08-16 | 2018-06-19 |
| Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Mifepristone - Cushing's Disease, Cushing's Syndrome | Phase 3 | Completed | Corcept Therapeutics | 4 | 2010-11-01 | 2014-03-18 |
| Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 198 | 2010-07-19 | 2018-04-05 |
| An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome mifepristone - Cushing's Syndrome | Phase 3 | Completed | Corcept Therapeutics | 30 | 2009-07-01 | 2014-04-02 |
| Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Calcium and Vitamin D, Placebo - Risperidone-induced Hyperprolactinemia | Phase 3 | Completed | Chadi A. Calarge | 47 | 2008-11-01 | 2017-12-26 |
| Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Lanreotide autogel 120 mg - Acromegaly | Phase 3 | Completed | Ipsen | 108 | 2008-05-01 | 2022-10-14 |
| Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Pasireotide, Octreotide - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 358 | 2008-02-11 | 2017-07-02 |
Showing 20 of 36. Sign in to see all of them.
Acromegaly (23) · Pituitary ACTH Hypersecretion (11) · Cushing Syndrome (5) · Pituitary Diseases (5) · ACTH Syndrome, Ectopic (4) · Pituitary Neoplasms (3) · Adrenal Cortex Neoplasms (2) · Choristoma (2) · Gigantism (2) · Hirsutism (2) · ACTH-Secreting Pituitary Adenoma (1) · Adenoma (1) · Diabetes Mellitus, Type 2 (1) · Fibrous Dysplasia, Polyostotic (1) · Growth Disorders (1)
Brain Diseases (36) · Central Nervous System Diseases (36) · Endocrine System Diseases (36) · Hypothalamic Diseases (36) · Nervous System Diseases (36) · Pituitary Diseases (31) · Bone Diseases (24) · Bone Diseases, Endocrine (24) · Musculoskeletal Diseases (24) · Neoplasms (9) · Endocrine Gland Neoplasms (6) · Neoplasms by Site (6) · Adrenal Gland Diseases (5) · Adrenocortical Hyperfunction (5)
lanreotide (7) · pasireotide (5) · pegvisomant (5) · Octreotide (4) · Corlux (3) · Mifepristone (3) · Duration of Therapy (2) · Cabergoline (1) · Calcium (1) · Osilodrostat (1) · Suspensions (1) · Vitamin D (1) · relacorilant (1)
Novartis Pharmaceuticals (9) · Ipsen (8) · Corcept Therapeutics (4) · Ambrilia Biopharma, Inc. (2) · Camurus AB (2) · Chiasma, Inc. (2) · Cortendo AB (2) · Chadi A. Calarge (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · Novartis (1) · Pfizer (1) · Seth Gordhandas Sunderdas Medical College (1) · Unity Health Toronto (1)
United States (21) · Italy (16) · Germany (15) · Spain (13) · France (12) · Poland (12) · United Kingdom (11) · Hungary (10) · Turkey (Türkiye) (10) · Netherlands (9) · Romania (9) · Belgium (8) · Canada (8) · Greece (8) · Russia (8)
Raphael Naudin, M.D. (2) · Andreas Moraitis, MD (1) · Chadi Calarge, M.D. (1) · Coleman Gross (1) · Coleman Gross, M.D. (1) · Coleman Gross, MD (1) · Constance Chik, MD (1) · Diego Ferone, M.D (1) · Fredric Cohen, MD (1) · Fredric J Cohen, MD (1) · Karim A Calis, Pharm.D. (1) · Maria Fleseriu, M.D., FACE (1)
PMID 25013998, PMID 26507877, PMID 40418492, PMID 18248639, PMID 19542735, PMID 19639415, PMID 19898989, PMID 21086246, PMID 21148630, PMID 21212103, PMID 22397653, PMID 22466348, PMID 23746264, PMID 23970725, PMID 24287689, PMID 24423301, PMID 25103549, PMID 25260838, PMID 25537481, PMID 25664604, PMID 26437217, PMID 26603536, PMID 27039081, PMID 27405306, PMID 28289402, PMID 29032078, PMID 29112461, PMID 31379734, PMID 31465533, PMID 31542384, PMID 31804965, PMID 31875276, PMID 32117045, PMID 32217809, PMID 32366244, PMID 32385851, PMID 33216275, PMID 33897615, PMID 34173129, PMID 34953531, PMID 35058882, PMID 35325149, PMID 39378125, PMID 39610378, PMID 41052284, PMID 41730814
2019 (2), 2004 (1), 2009 (1), 2014 (1), 2015 (1), K23MH085005 (1)